Trial Search Results

N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

The three agents, cyclophosphamide (CTX), bevacizumab (BV) and zoledronic acid (ZA), proposed on this study each have individual promise against neuroblastoma, have completed early pediatric testing, and are expected to be well tolerated when given in combination.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

New Approaches to Neuroblastoma Therapy Consortium

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):


  • Drug: Bevacizumab
  • Drug: cyclophosphamide
  • Drug: zoledronic acid


Phase 1


Inclusion Criteria:

   - Patients must be no more 30 years of age when enrolled on study.

   - Patients must have relapsed neuroblastoma, refractory neuroblastoma that had less than
   a partial response to standard treatment or persistent neuroblastoma that had at least
   a partial response to standard treatment.

   - Patients who have at least a partial response to standard treatment who still have
   neuroblastoma that can be seen on CT/MRI or MIBG scans must have a surgical biopsy
   done of the tumor to confirm that it is neuroblastoma. Patients with relapsed or
   refractory neuroblastoma do not need to have a biopsy done to enter on study.

   - Patients must have adequate heart, kidney, liver blood clotting and bone marrow
   function. Patients who have bone marrow disease must meet the bone marrow function
   criteria to enter the study.

   - Patients must have recovered from all prior chemotherapy and surgical procedures

Exclusion Criteria:

   - They are known to be sensitive to Bevacizumab.

   - They have a history of very high blood pressure which required intensive intervention

   - They are pregnant or breastfeeding

   - Neuroblastoma is present in the brain on a CT or MRI scan done at study entry.
   Patients with neuroblastoma found in the bones of the skull are eligible if there is
   no tumor mass associated with them pressing on the brain.

   - They have a history non healing wounds

Ages Eligible for Study

N/A - 30 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Pediatric Hematology/Oncology
Not Recruiting